Graybug Vision Stock

graybug.comHealthcare / Other HealthcareFounded: 2011Funding to Date: $160.77MM

Graybug Vision is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve.

Register To Buy and Sell Shares

For more details on financing and valuation for Graybug Vision, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Graybug Vision’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Graybug Vision.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Dan Salain
Chief Operating Officer
Charles Semba MD
Chief Medical Officer
Frédéric Guerard
Chief Executive Officer & Board Member
Peter Campochiaro MD
Justin Hanes Ph.D
Co-Founder & Board Member
Pamela Wapnick
Chief Financial Officer
Peter McDonnell MD

Board Members

Chau Khuong
Hansoo Keyoung
Cameron Wheeler Ph.D
Deerfield Management
Gerald Cagle Ph.D
Christy Shaffer Ph.D
Emmett Cunningham Ph.D
Clarus Ventures
Frédéric Guerard
Justin Hanes Ph.D

News Highlights

Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs
Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases includin
Updated on: Dec 6, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.